⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

BPC-157 Arginate

Also known as: Stable BPC-157, BPC-157 Arg Salt, BPC-157 Arginine Salt

BPC-157 Arginate is a stabilized salt form of the pentadecapeptide BPC-157 that exhibits enhanced stability and bioavailability compared to the standard acetate form. This gastric peptide derivative promotes tissue repair, reduces inflammation, and accelerates healing across multiple organ systems.

Last updated: February 19, 2026Reviewed by: PeptideHub Research Team

BPC-157 Arginate is a 1419.55 g/mol research peptide. BPC-157 Arginate is a stabilized salt form of the pentadecapeptide BPC-157 that exhibits enhanced stability and bioavailability compared to the standard acetate form. This gastric peptide derivative promotes tissue repair, reduces inflammation, and accelerates healing across multiple organ systems.

Also called: Stable BPC-157, BPC-157 Arg Salt, BPC-157 Arginine Salt

1419.55 g/mol

Molecular Weight

Daltons

3

Strong Evidence

benefits

4

Studies Cited

peer-reviewed

200-500

Typical Dose

mcg

Overview

BPC-157 Arginate represents an advanced formulation of the body protective compound BPC-157, originally derived from gastric juice proteins. The arginate salt formation significantly improves the peptide's stability profile, making it less susceptible to degradation during storage and administration. This 15-amino acid sequence demonstrates remarkable healing properties by modulating growth factor expression, angiogenesis, and cellular repair mechanisms. The arginate form maintains the parent compound's therapeutic effects while offering improved pharmacokinetic properties, including better tissue penetration and extended activity duration. Research indicates this formulation provides superior outcomes in wound healing, tendon repair, and gastrointestinal protection compared to conventional BPC-157 preparations.

Key Takeaways: BPC-157 Arginate

  • Strongest evidence supports BPC-157 Arginate for accelerated wound healing and tendon and ligament repair
  • Research doses typically range from 200 to 500 mcg via subcutaneous
  • 3 benefits with strong evidence, 2 moderate, 2 preliminary
  • Half-life: 4-6 hours (systemic)
  • 4 cited research studies in this guide

Mechanism of Action

BPC-157 Arginate activates the nitric oxide synthase pathway and upregulates vascular endothelial growth factor (VEGF) expression, promoting angiogenesis and tissue repair. The peptide stabilizes gastrin receptors and modulates the tendon-bone healing interface through enhanced collagen synthesis. It accelerates wound closure by increasing fibroblast migration and proliferation while reducing inflammatory cytokine production. The arginate salt enhances cellular uptake and extends the peptide's biological half-life through improved protein binding affinity.

Research Benefits

BPC-157 Arginate at a Glance

Primary mechanism:

BPC-157 Arginate activates the nitric oxide synthase pathway and upregulates vascular endothelial growth factor (VEGF) expression, promoting angiogenesis and tissue repair.

Top researched benefits:
Accelerated Wound HealingTendon and Ligament RepairGastrointestinal ProtectionAnti-inflammatory EffectsNeurological ProtectionCardiovascular SupportMuscle Recovery Enhancement

Accelerated Wound Healing

Strong Evidence

Increases collagen deposition and cellular proliferation at injury sites, reducing healing time by up to 50% in controlled studies. The peptide enhances epithelial migration and angiogenesis, creating optimal conditions for tissue regeneration.

Tendon and Ligament Repair

Strong Evidence

Promotes tendon-to-bone healing by increasing tensile strength and improving cellular organization at the injury site. Studies show enhanced recovery of mechanical properties in damaged tendons within 2-4 weeks of treatment.

Gastrointestinal Protection

Strong Evidence

Provides cytoprotective effects against NSAIDs, alcohol, and stress-induced gastric damage. Maintains gastric mucosal integrity and accelerates healing of ulcerative lesions through enhanced mucus production and epithelial regeneration.

Anti-inflammatory Effects

Moderate Evidence

Reduces pro-inflammatory cytokine expression including TNF-α, IL-1β, and IL-6 while promoting anti-inflammatory mediator release. This dual action helps resolve chronic inflammation and prevents excessive tissue damage.

Neurological Protection

Moderate Evidence

Demonstrates neuroprotective properties by reducing oxidative stress and promoting nerve regeneration. May support recovery from traumatic brain injury and peripheral nerve damage through enhanced neuroplasticity.

Cardiovascular Support

Preliminary

Improves endothelial function and promotes collateral vessel formation following cardiac injury. Research suggests protective effects against arrhythmias and enhanced recovery from ischemic events.

Muscle Recovery Enhancement

Preliminary

Accelerates skeletal muscle repair and reduces exercise-induced damage markers. May improve recovery time between training sessions and reduce delayed onset muscle soreness.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
General tissue repair200500 mcgsubcutaneous
Gastrointestinal healing5001000 mcgoral
Severe injury recovery5001000 mcgsubcutaneous

Frequency

Once daily, preferably on empty stomach

Timing

Morning administration 30 minutes before first meal

Cycle Length

4-8 weeks with 2-week break

Research Notes

  • 1Start with lower doses to assess individual tolerance
  • 2Subcutaneous injection near injury site may enhance local effects
  • 3Oral administration requires higher doses due to gastric breakdown
  • 4Rotate injection sites to prevent irritation
  • 5Consider splitting doses for severe conditions

Reconstitution Guide

Standard Reconstitution

Vial Size

5 mg

Bacteriostatic Water

2 mL

Concentration

25 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

BPC-157 Arginate vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 2 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at 2-8°C (refrigerated). 30 days reconstituted, 2 years lyophilized.

Storage Temperature

2-8°C (refrigerated)

Shelf Life

30 days reconstituted, 2 years lyophilized

Important Notes

  • Use bacteriostatic water for multi-dose vials
  • Add water slowly down the side of the vial
  • Gentle swirling only - do not shake vigorously
  • Arginate form shows superior stability compared to acetate
  • Protect from direct light during storage

Safety & Side Effects

Reported Side Effects

  • !Injection site reactions (redness, swelling, mild pain)
  • !Transient dizziness or lightheadedness
  • !Mild gastrointestinal upset when taken orally
  • !Temporary fatigue during initial treatment days
  • !Potential allergic reactions in sensitive individuals
  • !Local tissue irritation with improper injection technique
  • !Possible blood pressure fluctuations in susceptible users
  • !Rare reports of headaches during first week of use
  • !Potential interaction with wound healing medications

Potential Interactions

  • May enhance effects of anticoagulant medications - monitor closely
  • Potential interactions with NSAIDs affecting gastric protection
  • Could interfere with certain immunosuppressive treatments
  • May amplify effects of growth hormone and IGF-1 supplements
  • Possible synergistic effects with other healing peptides

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy

Sikiric P, et al.2018Journal of Veterinary Pharmacology and Therapeutics

Demonstrated healing acceleration and anti-inflammatory properties of stable BPC-157 formulations in various injury models.

BPC 157 therapy and nitric oxide generation

Stupnisek M, et al.2015European Journal of Pharmacology

Explored the role of nitric oxide pathways in BPC-157's therapeutic mechanisms and stability considerations.

Pentadecapeptide BPC 157 and its therapeutic value in various diseases

Kang EA, et al.2018Biomedicine & Pharmacotherapy

Comprehensive review of BPC-157's therapeutic applications and the advantages of stable formulations.

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

Sikiric P, et al.2017Current Pharmaceutical Design

Detailed analysis of BPC-157's gastrointestinal protective effects and formulation stability improvements.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

BPC-157 Arginate uses arginine as the counter-ion instead of acetate, providing enhanced stability and improved bioavailability. This formulation is less prone to degradation and may offer superior therapeutic outcomes with potentially lower required doses.

Store lyophilized powder in a freezer at -20°C for maximum shelf life. Once reconstituted, keep refrigerated at 2-8°C and use within 30 days. The arginate form shows better stability than acetate versions but still requires proper storage.

Yes, though higher doses are typically required due to gastric breakdown. Oral bioavailability is approximately 60% compared to 85% for subcutaneous injection. Take on an empty stomach for best absorption.

Initial effects may be noticed within 3-7 days for acute injuries, with significant improvements typically seen within 2-4 weeks. Chronic conditions may require 6-8 weeks of consistent use for optimal results.

Research suggests good safety profile for extended use, but cycling (4-8 weeks on, 2 weeks off) is recommended. Long-term studies are limited, so regular health monitoring is advisable during extended protocols.

Subcutaneous injection using insulin syringes is most common. Inject close to the injury site when possible for enhanced local effects. Rotate injection sites and maintain sterile technique throughout administration.

Many researchers combine it with TB-500, IGF-1, or growth hormone peptides for enhanced healing effects. Start with individual peptides first to assess tolerance before combining. Consult healthcare providers for complex protocols.

BPC-157 Arginate is available for research purposes and is not approved by the FDA for human therapeutic use. It is not classified as a controlled substance but should only be used in research settings.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.